- Home
- TEM vs INCY Comparison
TEM vs INCY Comparison
Compare TEM & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEM
- INCY
- Stock Information
- Founded
- TEM 2015
- INCY 1991
- Country
- TEM United States
- INCY United States
- Employees
- TEM N/A
- INCY N/A
- Industry
- TEM
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- TEM
- INCY Health Care
- Exchange
- TEM NYSE
- INCY Nasdaq
- Market Cap
- TEM 11.9B
- INCY 13.4B
- IPO Year
- TEM 2024
- INCY 1993
- Fundamental
- Price
- TEM $58.41
- INCY $68.72
- Analyst Decision
- TEM Buy
- INCY Hold
- Analyst Count
- TEM 12
- INCY 20
- Target Price
- TEM $65.09
- INCY $73.81
- AVG Volume (30 Days)
- TEM 10.1M
- INCY 1.9M
- Earning Date
- TEM 08-05-2025
- INCY 07-29-2025
- Dividend Yield
- TEM N/A
- INCY N/A
- EPS Growth
- TEM N/A
- INCY N/A
- EPS
- TEM N/A
- INCY 0.10
- Revenue
- TEM $803,315,000.00
- INCY $4,413,226,000.00
- Revenue This Year
- TEM $81.57
- INCY $13.48
- Revenue Next Year
- TEM $24.86
- INCY $10.35
- P/E Ratio
- TEM N/A
- INCY $709.82
- Revenue Growth
- TEM 42.93
- INCY 17.13
- 52 Week Low
- TEM $30.81
- INCY $53.56
- 52 Week High
- TEM $91.45
- INCY $83.95
- Technical
- Relative Strength Index (RSI)
- TEM N/A
- INCY 54.01
- Support Level
- TEM N/A
- INCY $66.85
- Resistance Level
- TEM N/A
- INCY $70.37
- Average True Range (ATR)
- TEM 0.00
- INCY 1.78
- MACD
- TEM 0.00
- INCY -0.30
- Stochastic Oscillator
- TEM 0.00
- INCY 41.60
About TEM TEMPUS AI INC
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.